ArticleFrontiers in oncology2025
Global trends and forecasts of nonalcoholic steatohepatitis causing liver cancer incidence and deaths.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic kidney disease due to hypertension in China, Japan, and the Republic of Korea: trends from the Global Burden of Disease Study 1990-2023.International urology and nephrology · 2026Article
- Artificial Intelligence in the Diagnosis and Prognostic Stratification of Hepatocellular Carcinoma: Current Evidence, Clinical Applications, and Future Perspectives.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive form, nonalcoholic steatohepatitis (NASH), has emerged as a leading cause of hepatocellular carcinoma (HCC). The burden of MASLD is increasing rapidly in parallel with the rising global prevalence of obesity and metabolic syndrome, affecting approximately 30% of the world's population. Objective: This study aimed to quantify global trends in NASH-related liver cancer incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 and to project the future disease burden through 2035. Methods: Data from the Global Burden of Disease Study 2021, encompassing 204 countries, were utilized to evaluate age-standardized incidence (ASIR), mortality (ASMR), and DALY rates (ASDR) across 21 regions and five Socio-demographic Index (SDI) categories, with stratification by age, sex, and geographical location. Future trends were projected using statistical modeling approaches, while decomposition analysis was employed to identify the key drivers of changes in disease burden. Results: From 1990 to 2021, global ASIR of NASH-related HCC increased by 25% (0.4-0.5 per 100,000), with an EAPC of +3.5% (95% UI: 3.4-3.6). ASMR rose by 150% (0.2-0.5 per 100,000; EAPC + 3.2%), and ASDR increased by 20% (9.6-11.5 per 100,000; EAPC + 2.9%).Regional disparities: Australasia saw the steepest rise (ASIR + 200%, EAPC + 7.2%; ASMR + 150%, EAPC + 6.9%). High-income North America followed (ASIR + 160%, EAPC + 5.3%).Age/sex differences: Incidence peaked in ages 85-89 (6.31 per 100,000 men; 5.56 per 100,000 women). Men had higher burden, for example, 55-59 years: male ASIR 1.28 vs. female 0.87 per 100,000. but gender gaps narrowed after age 75.Risk drivers: Metabolic factors such as high fasting glucose accounted for 29.7% of deaths in ages 80-84; smoking contributed 11.1% in ages 55-59.Projections: By 2035, ASIR will rise to 0.74 per 100,000 (+7% from 2021), driven by aging, population growth, and epidemiological changes (52% of incidence increase globally). Conclusion: NASH-related HCC burden exhibits accelerating global growth, concentrated in high-SDI regions. Prioritizing metabolic management and early screening is critical to mitigate future burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.